Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Regis McConnell who started this subject	7/22/2004 8:30:50 AM
From: scaram(o)uche	of 946

J Neurol Sci. 2004 Aug 15;223(1):81-6. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. Gonsette RE. National Center for Multiple Sclerosis, Vanheylenstraat 16, B_1820, Melsbroek, Belgium. Mitoxantrone (MX) has been approved by the Food and Drug Administration for the treatment of rapidly progressive multiple sclerosis (MS). Unfortunately, its long-term administration is prevented by the cardiotoxicity. Pixantrone (PIX) is an analogue of MX devoid of toxic effects on cardiac tissue and was developed as a replacement for other anthracenediones in cancer patients. With a view to an application in MS patients, experimental data demonstrated that PIX is as potent as MX in preventing acute experimental allergic encephalomyelitis development as well as the occurrence of relapses in the chronic model. Safety data from animal studies and from phase II trials in cancer patients confirm a very weak cardiotoxicity, if any. A phase I trial with PIX in patients with a rapidly progressive MS seems thus warranted.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next